YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial

Clinical trial NCT04500561 · UNKNOWN

Trial details

NCT number: NCT04500561
Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Diffuse Large B Cell Lymphoma

Start date: 2020-08-20
Primary completion: 2021-10-01
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.